High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 5, 2006, Pages 640-646

  Heinemann, V ^a   Stemmler, H J ^a   Wohlrab, A ^b   Bosse, D ^b   Losem, C ^b   Kahlert, S ^a   Rauthe, G ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Schloßbergklinik Oberstaufen ^*

^c Schloßbergklinik Oberstaufen   (Germany)

Author keywords

Anthracycline resistance; Cisplatin; Gemcitabine; Metastatic breast cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANALGESIC AGENT; ANTHRACYCLINE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATININE; FUROSEMIDE; GEMCITABINE; HEMOPOIETIC GROWTH FACTOR; TAXANE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 32544450815     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0093-5     Document Type: Article

References (23)

1. Achanta G, Pelicano H, Feng L, Plunkett W, Huang P (2001) Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 61:8723-8729
2. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147-159
3. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A (2002) Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62:2-8
4. Brodowicz T, Kostler WJ, Moslinger R, Tomek S, Vaclavik I, Herscovici V, Wiltschke C, Steger GG, Wein W, Seifert M, Kubista E, Zielinski CC (2000) Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 9:338-342
5. Burch PA, Maillard J, Hillman D (2000) Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer (MBC) and failure on prior chemotherapy: a North Central Cancer Treatment Group study (Abstract). Breast Cancer Res Treat 64:81
6. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13:2731-2736
7. Chaudry S, Abdel-Rahman HA, Patil R (2000) Prospective phase II study of weekly cisplatin-gemcitabine in refractory metastatic breast cancer (MBC) (Abstract). Proc Am Soc Clin Oncol 19:111
8. de la Pena HF, Tellez E, Bastarrachea J (2001) Gemcitabine plus cisplatin as a palliative treatment in metastatic or refractory breast cancer (MRBC) (Abstract). Proc Am Soc Clin Oncol 20:60b
9. Doroshow JH, Tetef M, Margolin K (2000) Significant activity of gemcitabine (Gem) and cisplatin (Ddp) in both heavily (H) and minimally (M)-pretreated metastatic breast cancer (Mbc) patients (Pts): a California Cnacer Consortium/ Loyola University Chicago trial (Abstract). Proc Am Soc Clin Oncol 19:155a
10. Galvez CA, Calmarini F, Curie M (2000) Monthly cisplatin (C) and gemcitabine (G) as second-line chemotherapy for patients with advanced breast cancer (Abstract). Breast Cancer Res Treat 64(1):81
11. Heinemann V (2002) Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clin Breast Cancer 1(Suppl 3):24-29
12. Kaplan EL, Meier P (1959) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
13. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS (2000) Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 18:2245-2249
14. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671
15. Peters GJ, Bergman AM, Ruiz vH, V, Veerman G, Kuiper CM, Braakhuis BJ (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72-79
16. Ruiz GC, de la Pena HF, Meza FA (2001) A phase II study of gemcitabine plus cisplatin in metastatic breast cancer (MBC) (Abstract). Proc Am Soc Clin Oncol 20:60b
17. Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG, Possinger K (1999) Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10:625-631
18. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
19. Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J, de Wit R (2001) Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66:83-87
20. Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM, Dieras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P (2001) Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60:303-307
21. van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ (1999) Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80:981-990
22. van Moorsel CJ, Veerman G, Bergman AM, Guechev A, Vermorken JB, Postmus PE, Peters GJ (1997) Combination chemotherapy studies with gemcitabine. Semin Oncol 24:S7
23. Yang LY, Li L, Jiang H, Plunkett W (2000) Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumour cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 6:773-781